Reprinted from Australian Family Physician Vol. 39, No. 10, october 2010

This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas: the COVID-19 Partners Platform; the use of COVID...-19 simulation exercises to test deployment strategies; the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies; the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool; the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings; recommendations for vaccination of pregnant and lactating women; supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely; the WHO licensed COVID-19 vaccines product-specific information; use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines; lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and updated additional resources at the end of each chapter. more

Orientations provisoires, 16 novembre 2020 Ce document d’orientation a été conçu à l’intention des autorités nationales chargées de gérer le déploiement, la mise en �...�uvre et le suivi des vaccins contre la COVID-19, ainsi que des partenaires qui fournissent le soutien nécessaire. Comme, dans la plupart des pays, la mise en place d’un mécanisme de déploiement et de vaccination du vaccin contre la COVID-19 relève du ministère de la santé, ce document vise à soutenir les pays dans l’élaboration de mécanismes de coordination entre tous les secteurs de leur gouvernement et entre les différentes parties prenantes. more